Kornimate/medical-research-clean huggingface dataset:
mechanisms of insulin facilitation of memory

Conditions: Memory Disorders

Summary: the study described in the present application will test the hypothesis that insulin mediated facilitation of memory in alzheimer's disease (ad) is achieved through enhanced glutamatergic neurotransmission due to improvements in cerebral glucose metabolism. the effect of a single dose of intranasal insulin on memory and cerebral glutamate concentrations in adults with mild ad or amnestic mild cognitive impairment (amci), the presumed prodromal phase of ad will be studied. successful completion of this study may set the stage for a larger-scale treatment trial of intranasal insulin for adults with memory disorders. however, the use of insulin in this manner at this point in time is purely experimental.

the specific aims of this project will be accomplished through a cross sectional repeated measures design in which 15 participants with mild ad or amnestic mci will undergo assessments of brain structure and function 15 minutes after a single dose of insulin (20 iu) or placebo. insulin and placebo conditions will be counterbalanced across participants. intranasal insulin or placebo administration: saline and insulin (novolog) will be ordered though the ut student health services pharmacy (sharon roberson, chief pharmacist) and stored at 4°c, according to standard pharmacy protocols. three ml doses of saline or insulin will be packaged in nasal spray bottles (e.g., spectrum pharmacy products bottles 969-17404p and actuators 551-24362p) designed to deliver 100μl dose with each spray. a total volume of 200μl will be delivered during each administration (one 100μl dose in each nostril).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of probable ad * age over 21 * clinical dementia rating of 0.5 or 1.0 * mini mental state exam score\>15 exclusion criteria: * preexisting diabetes * significant neurological disease that might affect cognition, other than ad, including stroke, parkinson's disease, multiple sclerosis * severe head injury with loss of consciousness \> 30 minutes or with permanent neurological sequelae * significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease * current use of anti-psychotic or anti-convulsant medications * current or previous use of hypoglycemic agents or insulin * mri contraindications * claustrophobia * pregnancy

Keywords: memory disorders alzheimer's disease
revaccination with pneumovax™ 23 in older japanese adults (v110-902)

Conditions: Pneumococcal Infection

Summary: the purpose of this study is to determine if revaccination with pneumococcal vaccine (pneumovax™ 23, v110) is well tolerated and produces an immune response in older japanese adults. the primary hypothesis being tested is that the geometric mean concentration of antibodies to pneumococcal polysaccharide serotypes 3, 6b, and 23f at 4 weeks after revaccination will be superior to that before revaccination in japanese adults who received a primary vaccination at least 5 years before revaccination.


Eligibility criteria:
inclusion criteria: * japanese participant * good health or any underlying chronic illness is documented to be in stable condition * revaccination group: received one documented pneumovax™ 23 vaccination at least 5 years before enrollment in the study * primary vaccination group: no prior history with pneumovax™ 23 vaccination exclusion criteria: * known allergy or sensitivity to any of the components of the study vaccine * history of pneumococcal conjugate vaccination * known or suspected immune dysfunction, immunosuppression, or autoimmune disease. participants with a history of cancer who are not actively treated and not immunosuppressed will be eligible * functional or anatomic asplenia * received immunoglobulin within 6 months before study vaccine or is planned during the study * received any investigational drugs or vaccines within 2 months before study vaccination * history of pneumococcal disease (positive culture from blood or other normally sterile site) * thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection * history of convulsion * previously diagnosed with immunodeficiency or has a close relative with congenital immune deficiency * participating in any other clinical trial
serotonin, serotonin genetics(tph2) and emotion and interference processing

Conditions: Healthy

Summary: the study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the tph2 genotype

based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social \& emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (atd) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fmri experiment. to further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. given that tph2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the tph2 genotype. to this end, healthy male tph2-gg or tph2-tt carriers will be recruited and will receive atd (100g) and placebo (102.3g) in a within subject design. to control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.

Eligibility criteria:
inclusion criteria: * healthy subjects without past or current psychiatric or neurological disorders * right-handedness exclusion criteria: * history of head injury; * medical or psychiatric illness. * high blood pressure, general cardio-vascular alterations * history of drug or alcohol abuse or addiction. * allergy against medications or general strong allergies * sleep disorders. * visual or motor impairments

Keywords: acute tryptophan depletion tryptophan hydroxylase 2 gene emotion
cancer venous thromboembolism (vte)

Conditions: Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer

Summary: the primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of lmwh) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (vte) or major bleeding in subjects with vte associated with cancer during a 12-month study period. if non-inferiority is established, lmwh/edoxaban will be compared with dalteparin for superiority.


Eligibility criteria:
inclusion criteria: * male or female subjects with age ≥ 18 years or the otherwise legal lower age according to the country of residence; * confirmed acute lower extremity proximal dvt or pe for which long term treatment with low molecular weight heparin (lmwh) is indicated; * cancer, other than basal-cell or squamous-cell carcinoma of the skin; * able to provide written informed consent. exclusion criteria: * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of dvt and/or pe; * treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) vte episode prior to randomization; * active bleeding or high risk for bleeding contraindicating treatment with lmwh or edoxaban; * any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;

Keywords: active cancer with metastasis
outpatient total joint arthroplasty in dedicated daycare facility vs standard patient ward

Conditions: Arthropathy of Knee; Arthropathy of Hip

Summary: the purpose of this single center randomized controlled trial (rct) is to investigate whether outpatient arthroplasty surgery in a dedicated daycare facility will improve discharge on day of surgery, as opposed to surgery followed by subsequent stay in the ward and also same day discharge, without compromizing safety and outcome.

introduction of fast-track total hip arthroplasty (tha) and total knee arthroplasty (tka) has led to a decrease in length of stay without compromising patient safety and clinical outcome . in recent years outpatient tha and tka has gained popularity, especially as major focus is placed on reducing cost and increasing efficiency in all medical treatments . studies have shown outpatient arthroplasty to be feasible both for tha and tka patients , with up to 70% of unselected patients being potentially eligible for outpatient surgery. various results are published on success rate of discharged patients on the day of surgery, ranging from 25% to 99% , depending on patient selection and logistic setup. while the majority of published studies utilizes a modern fast-track setup with early mobilization and multimodal pain treatment, the optimal logistic setup remains unknown. the purpose of this single center randomized controlled trial (rct) is to investigate whether outpatient arthroplasty surgery in a dedicated daycare facility will improve discharge on day of surgery, as opposed to surgery followed by subsequent stay in the ward and also same day discharge, without compromizing safety and outcome.

Eligibility criteria:
inclusion criteria: * patients with clinical and radiological osteoarthritis of the hip suitable for primary cementless tha and patients with clinical and radiological osteoarthritis of the knee suitable for primary cruciate retaining (cr) tka * age 18-80 * american society of anesthesiologists (asa) score (1-2) * bmi \<35 * interested in and motivated for same day discharge * family or relatives to be present for \>24 hours after discharge * able to understand and give consent to the study exclusion criteria: * unable to provide care at own home on day of surgery for \>24 hours after discharge
psoreal - managing psoriasis in the real world

Conditions: Psoriasis Vulgaris

Summary: multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product enstilar® (calcipotriol/betamethasone dipropionate).

this multinational study aims to describe current treatment patterns and outcomes in the diversity of the real life setting: local differences in access to drugs and current treatment practices, and regional cultural differences, covering adult patients of all backgrounds, sex, socio-economic standing, health background, comorbidity and co-medication. a total of around 400 real-life prescribers in 3-8 countries are expected to participate over the years, with each country contributing data to the study for around 2 years, starting data collection within the first year after local market introduction of enstilar®. the real-life prescribing and utilization patterns of topical prescription products approved for treatment of psoriasis vulgaris in the individual participating countries will be mapped and performance of the products in real life will be investigated based primarily on baseline data from investigators and patient reported data contributed by the individual patient for 1 year. patients are expected to enter data on their electronic device at baseline and at times of treatment changes and other key events, and investigators are expected to contribute data after each contact with the patient. patients will be approached for informed consent to participate in the study after their individual treatment plan has been decided. the study aims to include two patients on other topical treatment for every patient planned to receive enstilar® in order to ensure a sufficient sample of enstilar® treated patients to capture the diversity of real-life prescription patterns in patients not on enstilar®, and to allow for sufficiently powered comparisons between enstilar® and other real-world treatment strategies. a systematic approach will be used to select eligible patients to be approached for study participation in order to minimize selection bias and control seasonal variations.

Eligibility criteria:
inclusion criteria: * adult age * psoriasis vulgaris * plaques on the body (trunk and/or extremities) of at least mild severity at time of inclusion * decision to prescribe a topical psoriasis treatment for body use where the prescription is not a routine renewal of the prescription of an ongoing therapy * signed and dated informed consent * willingness and ability to enter personal disease and treatment information onto a secure webpage during the one year individual study period, using their existing access to a pc or electronic device and a personal access code. exclusion criteria: * participation in the active treatment phase of a clinical trial * previous enrollment in the study

Keywords: topical real-world local standard of care non-interventional calcipotriol
mitomycin-c application for prk

Conditions: Myopia

Summary: to evaluate the safety and efficacy of 5 seconds mitomycin-c (mmc) application during photorefractive keratectomy (prk) for patients with low myopia.


Eligibility criteria:
inclusion criteria: * the inclusion criteria was ablation depth less than 65 µm, * a stable refractive error for at least 1 year * corrected distance visual acuity (cdva) of 0.1 logmar or better. exclusion criteria: * patients with keratoconus suspect, * excessive dry eyes, * impaired wound healing processes, * lenticular changes, * corneal dystrophy, * history of ocular surgery, * anterior or posterior uveitis, * glaucoma and retinal diseases were excluded.
effects of conductive exercises on motor skills among the children with cp

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is defined as a neurodevelopmental disorder in which there are abnormalities of motor skills, muscle tone ,and, movement and is caused by injury to the developing brain. risk factors for cerebral palsy are most probably intrauterine exposure to infection or inflammation and disorders of coagulation.cerebral palsy (cp) is classified as spastic, athetoid, tremor, rigidity, ataxic, atonic, and mixed. cerebral palsy (cp) is the most common cause of physical disability in early childhood and overall, the cp rate is between 2 and 3 per 1000 live births.there are several interventions to manage cerebral palsy depending upon the severity and type of cerebral palsy and hence requires a multidisciplinary setting for proper improvement and management.one of the important intervention is conductive education including conductive exercises (ce). conductive education (ce) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program.

group a: experimental group: group a will perform conductive exercises (ce) in addition to routine physical therapy. conductive exercises program will include squat-position, rising from squat to stand, sitting on the stool, prone lying, high kneeling and half kneeling, sitting, lying and high kneeling, walking in parallel bars, sitting to standing, floor to standing, picking up toys from the floor, balance on one foot on different surfaces and heights, crawling over foams of different sizes and shapes, climbing steps or stairs sometimes while carrying a toy. these exercises will improve motor skills and activities of daily living by improving the muscle strength. group b: control group: group b will perform routine physical therapy (rpt) alone. active and passive movements, passive stretching, strengthening exercises, weight bearing exercises. both the groups will receive intervention for 45 minutes per session 5 days in a week for 2 month. data will be collected at baseline and after the completion of the study. data will be collected after ethical approval and consent. all the personal information of the patient will be kept confidential.

Eligibility criteria:
inclusion criteria: * spastic cerebral palsy * gmfcs level i, ii and iii * age group 6 to 12 years * either gender exclusion criteria: * had a botulinum injection for reduce spasticity * subjects with any cardiac problem(congenitally) * children who are having visual and hearing deficits

Keywords: adls, cerebral palsy, motor skills, quality of life
safety and effectiveness of the pxl-platinum 330 system for cxl using riboflavin solution

Conditions: Keratoconus; Pellucid Marginal Corneal Degeneration; Corneal Degeneration; Corneal Ectasia

Summary: safety and effectiveness of the pxl-platinum 330 system for corneal collagen cross-linking in eyes with corneal thinning conditions

patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the peschke pxl-330 system using pulsed, accelerated energy delivery. patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, pachymetry, and visual function.

Eligibility criteria:
inclusion criteria subjects who have one or both eyes that meet criteria 1-4 and also meet at least 1 or more of criteria 5-11 will be considered candidates for this study: 1. 8 years of age or older 2. signed written informed consent 3. willingness and ability to comply with schedule for follow-up visits 4. contact lens wearers only: 1. removal of contact lenses for the required period of time prior to the screening refraction: contact lens type minimum discontinuation time soft 3 days soft extended wear 3 days soft toric 3 days rigid gas permeable 2 weeks 2. subjects who cannot function without wearing their contact lenses, may forgo discontinuation of contact lenses. 5. presence of central or inferior steepening. 6. axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration 7. presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: 1. fleischer ring 2. vogt's striae 3. decentered corneal apex 4. munson's sign 5. rizzutti's sign 6. apical corneal scarring consistent with bowman's breaks 7. scissoring of the retinoscopic reflex 8. crab-claw appearance on topography 8. steepest keratometry (kmax) value ≥ 47.20 d 9. i-s keratometry difference \> 1.5 d on the pentacam/orbscan map or topography map 10. posterior corneal elevation \>16 microns 11. thinnest corneal point \>300 microns
noise, a risk for heart in airplane pilots

Conditions: Pericarditis

Summary: study of noise generated by military-type aircraft and equipment maintenance in relation to non-auditory effects that impact with the body of the crew and ground staff can cause cardiac pathologies hypothesis of work: the pilots and the technical personnel of maintenance that work before the exhibition of noise generated by planes hunt f-16, or equipments of maintenance of the same ones, present major risk of a cardiac affectation, which demonstrates in changes in the normal pace of the heart, in his function of bomb or in hemodynamic conditions.

the work area military airport is characterized by low frequency noise in sound pressure levels exceeding 100 db, smashing into the body of pilots and ground staff. it found variations in the thickness of the pericardium and deviation measures ejection fraction

Eligibility criteria:
inclusion criteria: * exposure to noise from military aircraft exclusion criteria: * inactive personal or vacation

Keywords: echocardiogram electrocardiographic risk factors noise
evaluation of acute pain in maltreated children

Conditions: Pain

Summary: the hypothesis of this study is nonrecognition by the medical team of pain in maltreated children. these children would have a particular painful behaviour, "quiet". the management of their pain would be then unsuited, which could explain their complex relation with the pain in the adulthood. a pilot study realized in the chu of nantes on 11 files of maltreated children showed that they had very low scores of evaluation of the pain, in spite of severe traumatisms. there is, at the moment, no data in the literature on the acute pain of the maltreated children.


Eligibility criteria:
inclusion criteria: * age between 0 and 6 years * consultation in the emergency cares for traumatism with type of fracture and/or burn * time of the traumatism lower than 24 hours * information of the two parents or the parental authority and collection of the non-opposition. exclusion criteria: * old superior at 6 years * any type of traumatism other than a fracture and/or a burn * traumatism without possible dating or with a time of consultation higher than 24 hours * opposition of the parents formulated after their information by the medical team * child who can not have an evaluation of the pain with the chosen scales

Keywords: pediatry ill-treatment pain maltreated children
the effects of ankle foot orthoses (afos) on mobility in persons with multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to investigate the impact of ankle foot orthoses (afos) on the spatial and temporal gait parameters, electromyography (emg), walking endurance, and quality of life in select individuals living with ms. the hypotheses of the study are: 1. individuals who are fit with an afo will demonstrate improvements in spatial and temporal gait parameters 2. individuals who are fit with an afo will demonstrate improvements in walking endurance. 3. individuals who are fit with an afo will demonstrate improvements in muscle firing profiles/emg measures. 4. individuals who are fit with an afo will demonstrate improvements in quality of life.

this is a non-randomized, single group (n=15), repeated measures study. the outcome measure for the study include: 1. gaitrite system for step length, 2. emg of the anterior tibialis, gastrocnemius, soleus, and vastus lateralis muscles, 3. 6 minute walk test (gait endurance) 4. 12-item ms walking scale (quality of life assessment). this study will be 24 weeks long. over the 24-week period, the subject will participate in 14 gait training sessions which will be at weeks 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 17, 20 and 23. the treatments will be 45-60 minutes in duration. outcome measures (all or part) will be assessed at the following times: initial (t1), week 5 (t2), week 13 (t3), and week 24 (t4). subjects will be closely monitored throughout the 24 week study and will be un-enrolled by self-request or the following medical reasons: 1. acute exacerbation of ms symptoms, 2. new diagnosis with direct consequences affecting gait training, 3. inability to tolerate the afo.

Eligibility criteria:
inclusion criteria: * individuals with a primary diagnosis of multiple sclerosis * individuals who are able to maintain a walking velocity of 30 cm/sec for at least 2 minutes independently or with the use of a single tip assistive device. * could have current or past history of single or bilateral afo use, including neuroprostheses * evidence of weakness in plantarflexors exclusion criteria: * the presence of co-morbidities (neuromuscular or musculoskeletal) that would negatively impact gait training * individuals with bmi with \>/= 40kg/m2 * individuals with range of motion deficit in the ankle limiting passive range of motion to neutral dorsiflexion * individuals that plan to begin the use of ampyra during the course of the study * individuals for whom the cost of an orthosis would represent a financial burden * individuals who are receiving concurrent physical therapy services elsewhere * msnq of \>22

Keywords: multiple sclerosis gait ankle foot orthosis (afo)